IVIG for Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

Myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) is an increasingly recognized disease for which treatment pathways are still being developed. This retrospective multicenter cohort study evaluated intravenous immunoglobulin (IVIG) maintenance for relapse prevention. Of 876 patients with MOGAD, 511 were receiving long-term immunosuppressive maintenance therapy and 59 were receiving IVIG.

IVIG was first-line therapy in 25% and second-line (due to failure of or intolerance to other treatment) in 75%. Initial dosing for most patients was every 4 weeks; 34% received 0.4 g/kg, 34% 1 g/kg, and 32% 2 g/kg. Relapses occurred in 34% on IVIG maintenance; median annualized relapse rate decreased from 1.4 before IVIG initiation to …